期刊文献+

阿齐沙坦原料药有关物质的检查 被引量:3

Related substances determination of azilsartan bulk drug
下载PDF
导出
摘要 目的建立阿齐沙坦原料药有关物质检查方法并对其进行质量评价。方法色谱柱采用华谱Unitary-C18(250 mm×4.6 mm,5μm),流动相为磷酸盐缓冲液(1 000 m L中含40 mmol磷酸二氢钾和3 m L三乙胺,磷酸调节p H为3.60)-甲醇(体积比为40∶60),检测波长为227 nm,柱温为30℃,流速为1.0 m L·min-1,进样量为20μL。采用不加校正因子的主成分自身对照法计算有关物质含量。结果在建立的色谱条件下,阿齐沙坦原料药中阿齐沙坦峰和杂质峰之间分离度良好,杂质A在质量浓度0.06~0.72 mg·L^(-1)内线性关系良好(r=0.999 9),平均回收率为100.0%,RSD为1.52%(n=9);杂质B在质量浓度0.18~0.60 mg·L^(-1)内线性关系良好(r=0.999 7),平均回收率为101.5%,RSD为0.83%(n=9)。结论该方法可以用来控制阿齐沙坦原料药的质量。 Objective In order to evaluate the quality of azilsartan bulk drug,two main impurity A and impurity B of azilsartan were synthesized and HPLC method was established to determine the related substances of azilsartan. Methods The HPLC system was equipped with ACCHROMUnitary-C18column( 250 mm ×4. 6 mm,5 μm) and phosphate buffer solution( weighing potassium phosphate monobasic 5. 4 g and triethylamine 3 m L,adding 1 000 m L water to dissolve and adjusting the p H to 3. 60 with phosphoric acid)-methanol( V / V,40:60) as mobile phase. Detection wavelength was set at 227 nm,column temperature was set at 30 ℃,and the flowrate was 1. 0 m L·min^- 1,the injection volume was 20 μL. The method of main component self-compare without correction factor was applied to the calculation of related substances.Results The chromatographic conditions established in this paper shows good separation between azilsartan peak and impurities peak. For impurity A,the linear ranges was 0. 06- 0. 72 mg·L^-1,r = 0. 999 9,and the average recovery was 100. 0%,RSD was 1. 52%( n = 9). And for impurity B,the linear ranges was 0. 18-0. 60 mg·L^-1,r = 0. 999 7,and the average recovery was 101. 5%,RSD was 0. 83%(n = 9). Conclusions The method is sensitive,durability,accurate and can be used for quality control of azilsartan bulk drug.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2017年第2期147-152,共6页 Journal of Shenyang Pharmaceutical University
关键词 阿齐沙坦 有关物质方法学 校正因子 质量评价 azilsartan related substances methodology correction factor evaluation of quality
  • 相关文献

参考文献3

二级参考文献45

  • 1邢艇,袁如玉.关于高血压治疗性疫苗的研究进展[J].临床荟萃,2009,24(17):1553-1555. 被引量:1
  • 2丛丽,俞茂华,李益明.血管紧张素转化酶抑制剂及血管紧张素受体拮抗剂与心脏保护[J].中国临床医学,2004,11(4):670-671. 被引量:5
  • 3张伟,朱卫忠,黄金华.莫索尼定与可乐定对自发性高血压大鼠作用的比较[J].中国临床药理学与治疗学,2004,9(12):1415-1419. 被引量:5
  • 4PhRMA. New medicines database [EB/OL]. ( 2009 - 11 - 05 ) [2010 - 05 - 06]. http ://newmeds. phrma. org/results, php? skin = phrma& drug = &indication = 38&company = &status =.
  • 5Clinical Trials. gov. An evaluation of the effects of LC1699 on cortisol in patients with hypertension [ EB/OL ]. ( 2010 - 02 - 22) [ 2010 - 05-05]. http ://clinicahrials. gov/ct2/show/NCT00817414.
  • 6Clinical Trials. gov. Efficacy and safety of TAK-536 in subjects with essential hypertension [ EB/OL]. (2009 - 01 - 24) [ 2010 - 05 - 06 ]. http://clinicaltrials, gov/ct2/show/NCTO07595519. term = TAK-536&rank = 1.
  • 7Japan Pharmaceutical Information Center. Phase 3 study of TAK- 536 ( confirmatory trial) [EB/OL]. (2009 - 01 - 24 ) [2010 - 05 -06]. http://www. clinicaltrials. jp/user/cteDetail_e.jsp [2009/06/12 13 : 32 : 37].
  • 8Gilead Sciences,Inc. Phase III study of Gilead's darusentan for resistant hypertension meets primary endpoints[EB/OL]. (2009 - 04 - 02 ) [2010 - 05 - 06]. http://www. gilead. com/pr_ 1273012.
  • 9Gilead Sciences,Inc. Second pivotal phase III study of Gilead's darusentan for resistant hypertension misses primary endpoints [EB/OL]. (2009-12-06) [2010-05 -06]. http://investors. gilead, corn/phoenix, zhtmt? c = 69964&p = irol-newsArti- cle &ID = 1365747&highlight =.
  • 10MARKI HP, BINGGELI A, BITTNER B, et al. Piperidine renin inhibitors : from leads to drug candidates[J]. II Farmaco( S0014- 827X) ,2001,56(1 -2) :21 -27.

共引文献23

同被引文献20

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部